Benign Conditions

October 25th 2024

The approval is supported by data from the phase 3 SURE 1 and REASSURE trials.

October 15th 2024

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder.”

September 19th 2024

"A global consensus on standardization of terminology, separation of LUTS vs pain for outcome, HL positivity and negativity, markers for disease, and the role of new interventions for local vs systemic therapy is needed," writes Gopal H. Badlani, MD.

September 9th 2024

Follow Urology Times' coverage of the full-day FDA advisory committee meeting regarding Iterum Therapeutics' new drug application for oral sulopenem for uncomplicated urinary tract infection.